Meta Pixel

News and Announcements

OpenDNA Launches New Tool from AI System

  • Published October 03, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

KEY TAKEAWAYS:

  • OpenDNA Ltd (ASX: OPN) has launched it’s newest product, Synapse, utilising its AI systems.
  • The tool will allow customers with a deeper insight into the interests and psychographics of their users.
  • This will provide OpenDNA customers business-ready tools and actionable data.

Highly experienced developer and fund manager, OpenDNA Ltd (ASX: OPN) has launched it’s newest tool, Synapse, a suite of business tools to allow customers a thorough understanding of their users’ interests and psychographics.

Consumers utilizing Synapse can more effectively hit, retain, and convert users of their services. Depending on the business team concentrating on acquiring new users, upselling existing buyers, or effortlessly deepening engagement of content consumers, Synapse renders concise tools to elevate their specific metrics.

OpenDNA’s CEO and MD had informed the ASX that “the release of Synapse enables the power of the OpenDNA AIS platform to grow exponentially, by giving our customers new and robust ways of looking and acting on the data and insights that the platform provides. We are continually exploring ways to leverage our AI technology and to deliver relevant, practical outcomes for customers which improve the already-compelling business proposition that our personalisation technology provides. We understand our customers’ requirements for business-ready tools and actionable data – not just data for data’s sake – and Synapse comprehensively addresses those requirements.”

About OpenDNA Ltd (ASX: OPN)

To businesses, OpenDNA provides real-time insights into their individual customers’ behaviour which allows them to better predict their needs. This enables businesses to deliver a more relevant customer experience at an individual level, which drives increased revenue. OpenDNA’s artificial intelligence and machine-learning system automatically creates detailed psychographic user profiles, which helps deliver better business outcomes.

Request Information

Capital Insights
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t

The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.

Capital Insights
Following the Billions: Where the Hyperscalers are Betting on the Future

The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.

Join over 45,000+ sophisticated investors

Join Now